9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology

Human Pathology

Volumn 40, Issue 12, 2009, Pages 1783-1789

  Kawauchi, Shigeto ^a   Sakai, Hajime ^a   Ikemoto, Kenzo ^a   Eguchi, Satoshi ^a   Nakao, Motonao ^a   Takihara, Hirofumi ^b   Shimabukuro, Tomoyuki ^c   Furuya, Tomoko ^a   Oga, Atsunori ^a   Matsuyama, Hideyasu ^a   Takahashi, Mutsuo ^a   Sasaki, Kohsuke ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c UBE INDUSTRIES LTD   (Japan)

Author keywords

9p21 index; Bladder washing cytology; Fluorescence in situ hybridization; Recurrence; Urinary bladder; Urothelial carcinoma

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER IRRIGATION; CANCER RECURRENCE; CANCER SURVIVAL; CENTROMERE; CHROMOSOME 9; CHROMOSOME 9P; CHROMOSOME 9P21; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOLOGY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; HUMAN; MAJOR CLINICAL STUDY; MALE; TRANSURETHRAL RESECTION; UROGENITAL TRACT TUMOR;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; IRRIGATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 70449093749     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.06.011     Document Type: Article

References (25)

1. Lopez-Beltran A., Knowles M.A., Sauter G., et al. Infiltrating urothelial carcinoma. In: Eble J.N., Sauter G., and Epstein J.I. (Eds). World Health Organization classification of tumors: pathology and genetics of tumors of the urinary system and male genital organs. 1st ed (2004), IARC Press, Lyon, France 90-109
2. Donat S.M. Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am 30 (2003) 765-776
3. Kiemeney L.A., Witjes J.A., Heijbroek R.P., Verbeek A.L., and Debruyne F.M. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 150 (1999) 60-64
4. Bastacky S., Ibrahim S., Wilczynski S.P., and Murphy W.N. The accuracy of urine cytology in daily practice. Cancer 87 (1999) 118-128
5. Ramakumar S., Bhuiyan J., Besse J.A., et al. Comparison of screening methods in the detection bladder cancer. J Urol 161 (1999) 388-394
6. Spruck C.H., Ohneseit P.F., Gonzalez-Zulueta M., et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54 (1994) 784-788
7. Wu X.R. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5 (2005) 713-725
8. Woff E.M., Liang G., and Jones P.A. Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2 (2005) 502-510
9. Sokolova I.A., Halling K.C., Jenkins R.B., et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2 (2000) 116-123
10. Zellweger T., Benz G., Cathomas G., et al. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer 119 (2006) 1660-1665
11. Skacel M., Fahmy M., Brainard J.A., et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 169 (2003) 2101-2105
12. Ikemoto K., Furuya T., Matsuda K., et al. Multicolor FISH and cytometric analyses allow classification of urothelial carcinomas into two subtypes, low- and high-grade tumors. Int J Oncol 25 (2004) 893-898
13. Esposti P.L., and Zajicek J. Grading of transitional cell neoplasms of the urinary bladder from smears of bladder washings. A critical review of 326 tumors. Acta Cytol 16 (1972) 529-537
14. Cairns P., Shaw M.E., and Knowles M.A. Initiation of bladder cancer may involve deletion of a tumor-suppressor gene on chromosome 9. Oncogene 8 (1993) 1053-1055
15. Ruppert J.M., Tokino K., and Sidransky D. Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res 53 (1993) 5053-5055
16. Orlow I., Lacombe L., Hannon G.J., et al. Deletion of p16 and p15 genes in human bladder tumors. J Natl Cancer Invest 87 (1995) 1524-1529
17. Orlow I., LaRue H., Osman I., et al. Deletions in the INK4A gene in superficial bladder tumors: association with recurrence. Am J Pathol 155 (1999) 105-113
18. Sherr C.J. The Pezcoller lecture: cancer cell cycles revised. Cancer Res 60 (2000) 3689-3695
19. Koss L.G. Cytology of tumors of the bladder. In: Koss L.G., and Melamed M.R. (Eds). Koss' diagnostic cytology and its histopathologic bases. 5th ed (2006), Lippincott Williams & Wilkins, Philadelphia (Pa) 791-809
20. Czerniak B., Chaturvedi V., Li L., et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 18 (1999) 1185-1195
21. ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ. Hum Pathol 39 (2008) 527-535
22. Zhang Y., Xiong Y., and Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92 (1998) 725-734
23. Hussussian C.J., Struewing J.P., Goldstein A.M., et al. Germline p16 mutations in familial melanoma. Nat Genet 8 (1994) 15-21
24. Merio A., Herman J.G., Mao L., et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1 (1995) 686-692
25. Dulaimi E., Uzzo R.G., Greenberg R.E., Al-Saleen T., and Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 10 (2004) 1887-1893